Hochschulschrift
Using iPSC-CMs to develop a new, 2D in vitro culture-based model for cardiomyocyte hypertrophy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Maße
-
31 cm
- Umfang
-
IX, 114 Seiten
- Sprache
-
Englisch
- Anmerkungen
-
Illustrationen, Diagramme
Technische Universität Dresden, Dissertation, 2023
- Ereignis
-
Veröffentlichung
- (wo)
-
Dresden
- (wann)
-
2022
- Urheber
- Beteiligte Personen und Organisationen
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 13:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
Entstanden
- 2022
Ähnliche Objekte (12)
Inhibition of cardiomyocyte hypertrophy by heterocyclic thiourylenes in vitro
Sumoylation-independent activation of Calcineurin-NFAT-signaling via SUMO2 mediates cardiomyocyte hypertrophy
Sumoylation-independent activation of calcineurin-NFAT-signaling via SUMO2 causes cardiomyocyte hypertrophy
Three-dimensional human pluripotent stem cell-derived cardiomyocyte models for investigating cardiac hypertrophy
Cardiomyocyte hyperplasia and immaturity but not hypertrophy are characteristic features of patients with RASopathies
Altered cellular protein quality control system modulates cardiomyocyte function in volume overload-induced hypertrophy
Amlexanox and forskolin prevents isoproterenol-induced cardiomyopathy by subduing cardiomyocyte hypertrophy and maladaptive inflammatory responses
Angiotensin-(1-9) prevents cardiomyocyte hypertrophy via miR-129-3p/PKIA/PKA signaling pathway
Analysis of splice-defect associated cardiac diseases using a patient-specific iPSC-cardiomyocyte system
Integrational modelling for molecular analysis in a CRISPR/Cas edited iPSC-cardiomyocyte model of Dilated Cardiomyopathy
The acute phase protein alpha-2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1, 2 and PI3 kinase, akt pathways
Benign prostatic hypertrophy
Inhibition of cardiomyocyte hypertrophy by heterocyclic thiourylenes in vitro
Sumoylation-independent activation of Calcineurin-NFAT-signaling via SUMO2 mediates cardiomyocyte hypertrophy
Sumoylation-independent activation of calcineurin-NFAT-signaling via SUMO2 causes cardiomyocyte hypertrophy
Three-dimensional human pluripotent stem cell-derived cardiomyocyte models for investigating cardiac hypertrophy
Cardiomyocyte hyperplasia and immaturity but not hypertrophy are characteristic features of patients with RASopathies
Altered cellular protein quality control system modulates cardiomyocyte function in volume overload-induced hypertrophy
Amlexanox and forskolin prevents isoproterenol-induced cardiomyopathy by subduing cardiomyocyte hypertrophy and maladaptive inflammatory responses
Angiotensin-(1-9) prevents cardiomyocyte hypertrophy via miR-129-3p/PKIA/PKA signaling pathway
Analysis of splice-defect associated cardiac diseases using a patient-specific iPSC-cardiomyocyte system
Integrational modelling for molecular analysis in a CRISPR/Cas edited iPSC-cardiomyocyte model of Dilated Cardiomyopathy
The acute phase protein alpha-2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1, 2 and PI3 kinase, akt pathways
Benign prostatic hypertrophy
Inhibition of cardiomyocyte hypertrophy by heterocyclic thiourylenes in vitro
Sumoylation-independent activation of Calcineurin-NFAT-signaling via SUMO2 mediates cardiomyocyte hypertrophy
Sumoylation-independent activation of calcineurin-NFAT-signaling via SUMO2 causes cardiomyocyte hypertrophy
Three-dimensional human pluripotent stem cell-derived cardiomyocyte models for investigating cardiac hypertrophy
Cardiomyocyte hyperplasia and immaturity but not hypertrophy are characteristic features of patients with RASopathies
Altered cellular protein quality control system modulates cardiomyocyte function in volume overload-induced hypertrophy
Amlexanox and forskolin prevents isoproterenol-induced cardiomyopathy by subduing cardiomyocyte hypertrophy and maladaptive inflammatory responses
Angiotensin-(1-9) prevents cardiomyocyte hypertrophy via miR-129-3p/PKIA/PKA signaling pathway
Analysis of splice-defect associated cardiac diseases using a patient-specific iPSC-cardiomyocyte system
Integrational modelling for molecular analysis in a CRISPR/Cas edited iPSC-cardiomyocyte model of Dilated Cardiomyopathy
The acute phase protein alpha-2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1, 2 and PI3 kinase, akt pathways